Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Germany.
Department of Nuclear Medicine, University Hospital Augsburg, Augsburg, Germany.
Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2566-2572. doi: 10.1007/s00259-020-05177-z. Epub 2021 Jan 15.
The radiolabelled somatostatin analogue [Lu]Lu-DOTA-EB-TATE binds to albumin via Evans blue, thereby increasing the residence time in the blood and potentially allowing more therapeutic agent to be absorbed into the target tissue during peptide receptor radionuclide therapy. It was tested in selected patients whether the substance is superior to [Lu]Lu-DOTA-TOC.
Activity kinetics in organs and tumours after [Lu]Lu-DOTA-EB-TATE and [Lu]Lu-DOTA-TOC were compared intraindividually in five patients with progressive somatostatin receptor-positive disease scheduled for radionuclide therapy.
In comparison to [Lu]Lu-DOTA-TOC, tumour doses per administered activity were higher for [Lu]Lu-DOTA-EB-TATE in 4 of 5 patients (median ratio: 1.7; range: 0.9 to 3.9), kidney doses (median ratio: 3.2; range: 1.6 to 9.8) as well as spleen doses (median ratio: 4.7; range 1.2 to 6.2) in all patients, and liver doses in 3 of 4 evaluable patients (median ratio: 4.0; range: 0.7 to 4.9). The tumour to critical organs absorbed dose ratios were higher after [Lu]Lu-DOTA-TOC in 4 of 5 patients.
Prior to a treatment with [Lu]Lu-DOTA-EB-TATE, it should be assessed individually whether the compound is superior to established substances.
放射性标记的生长抑素类似物[Lu]Lu-DOTA-EB-TATE 通过 Evans 蓝与白蛋白结合，从而增加血液中的停留时间，并在肽受体放射性核素治疗期间使更多的治疗剂被吸收到靶组织中。在选定的患者中测试了该物质是否优于[Lu]Lu-DOTA-TOC。
在五名计划接受放射性核素治疗的进展期生长抑素受体阳性疾病患者中，对[Lu]Lu-DOTA-EB-TATE 和 [Lu]Lu-DOTA-TOC 进行个体内比较。
与 [Lu]Lu-DOTA-TOC 相比，在 4 名患者中，4 名患者的肿瘤剂量与每单位给予的活性相比更高（中位数比值：1.7；范围：0.9 至 3.9），所有患者的肾脏剂量（中位数比值：3.2；范围：1.6 至 9.8）和脾脏剂量（中位数比值：4.7；范围 1.2 至 6.2），4 名可评估患者中有 3 名肝脏剂量（中位数比值：4.0；范围：0.7 至 4.9）。在 4 名患者中，[Lu]Lu-DOTA-TOC 后肿瘤与关键器官吸收剂量比更高。
在使用[Lu]Lu-DOTA-EB-TATE 治疗之前，应单独评估该化合物是否优于已建立的物质。
